Invention Grant
- Patent Title: scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
-
Application No.: US16669211Application Date: 2019-10-30
-
Publication No.: US11325971B2Publication Date: 2022-05-10
- Inventor: Huawei Qiu , Clark Pan , Julie Bird
- Applicant: GENZYME CORPORATION
- Applicant Address: US MA Cambridge
- Assignee: GENZYME CORPORATION
- Current Assignee: GENZYME CORPORATION
- Current Assignee Address: US MA Cambridge
- Agency: Steptoe & Johnson LLP
- Agent Z. Ying Li; Mauricio Alvarez
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22 ; C07K16/46 ; C12N15/11 ; C12N15/62 ; C07K16/00 ; A61K39/00
Abstract:
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
Information query
